Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy.
about
Prevention of Hepatitis B reactivation in the setting of immunosuppressionHepatitis B virus reactivation with rituximab-containing regimenManagement of patients with hepatitis B who require immunosuppressive therapyHepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinomaA randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.Prevention of hepatitis B virus reactivation under rituximab therapy.Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinomaChemotherapy-related reactivation of hepatitis B infection: updates in 2013.Hepatitis B virus X protein enhances cisplatin-induced hepatotoxicity via a mechanism involving degradation of Mcl-1.Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma.The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder systemHepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic ChemotherapyDoxorubicin Activates Hepatitis B Virus Replication by Elevation of p21 (Waf1/Cip1) and C/EBPα Expression.Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors.Screening for hepatitis B in patients with lymphoma.Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization.Management of hepatitis B reactivation in patients receiving cancer chemotherapy.Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective studyScreening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis.New dicoumarol sodium compound: crystal structure, theoretical study and tumoricidal activity against osteoblast cancer cells.Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatmentsSystemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study.Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinomaHepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experienceDownregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF.Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinomaHepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement.Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation.Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Hepatitis B virus reactivation associated with anti-neoplastic therapy.Reactivation of hepatitis B virus in patients receiving chemotherapy.Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy.Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents.Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.
P2860
Q26747023-A30CB5B7-87F7-45C7-8A02-8FA8A47790D3Q26830484-E1691C6B-7384-4A41-9F80-C13D8D08DE93Q26853490-CA5528D7-4B78-4CF4-BE07-0B8D0D6699B6Q28076703-237E8C91-9C30-48B9-9E35-726274D51B3CQ28392783-A1D9E602-9086-4A13-87B3-19B78E886C7EQ28394414-8DDDD5F6-6A6F-4635-847D-8F552DA0F9FEQ33368982-634FF17E-4604-4259-9EB0-2D6BE66E4FFAQ33390799-07D04D80-34D0-4F82-8F05-5B655AD683A5Q33742856-DF3F2BA0-0EB6-4FB1-851E-F81339E1F206Q34404991-1C4F036B-C732-4493-986E-65F2F2AD7B51Q34742600-425C90BD-8C18-47A7-A824-93DE6BC2CB69Q34974883-895A44E8-2D40-4A9F-840B-64378F6EA314Q35051831-7A77D179-583C-4FDE-ABFA-F164C6925C11Q35057889-7FFB95FE-9549-4760-B4A4-24FEF5470AA5Q35567748-54F07FE7-F0D0-400A-8BD4-238BD94F93F2Q35677319-F2AEC556-26FD-4589-AB0E-4F59E510C938Q35801644-B7FDBE5B-92B4-4ED5-9EA7-4466F9A25879Q35875680-1FA295E4-14B3-4566-AD74-CD4FF4D09076Q36058282-51240BE4-454F-49A8-AFE1-8383DB13E4A1Q36121202-ED1352AA-1471-4AE0-A75B-ED894AAE5288Q36220459-18545611-3F70-4064-B9AC-6892F5E9C8A7Q36616847-BD380BF2-FFB6-460D-A619-5E3ECD3C8BF3Q36752181-E33434E5-E41E-4399-877E-8979AE633BAFQ36957087-808EDA0D-C566-44D8-B5CD-2C5C1E29BA1DQ37027906-566A401B-5F8B-4E5E-AF53-F7678FA7A596Q37050501-7ECD46A3-29A3-486A-BD95-8CCBC459ADBBQ37127099-4941A963-FDE2-4698-BB72-2C71BE858278Q37179530-A2EEE6B2-A3C6-4B2B-B90A-C98941AF380AQ37205405-A165DB53-172C-4936-9359-B03E37C56298Q37327584-3F6779F0-5005-46D5-9138-9B514F0270B7Q37716493-90D98D7E-0F7B-47C1-AD33-C8FAEE31745EQ37764963-8559E93D-3929-4173-8110-E77069D45B76Q37820114-6C7F5994-7491-4523-8777-5C7918D88F65Q37912229-FC72430A-4948-4B57-AC43-60A414EA313BQ37978202-CEFED9F1-798B-4772-BDC8-CD3D9556BE4FQ38047362-5F74591F-29FF-4EB2-9844-A9438B39CDC4Q38062818-15D11D61-DD67-4625-B9A3-D48FABEF2D70Q38224439-A310D418-232B-4818-B0BA-CE480E3378F8Q38334777-C741B132-2BB0-4379-9D96-59ECB7D4770CQ38815080-19552D99-1BAF-461F-B909-CB51BCE9EE4C
P2860
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@ast
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@en
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@nl
type
label
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@ast
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@en
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@nl
prefLabel
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@ast
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@en
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@nl
P2093
P356
P1433
P1476
Hepatitis B reactivation in pa ...... ergoing systemic chemotherapy.
@en
P2093
A T C Chan
P J Johnson
P S K Chan
T W T Leung
P304
P356
10.1093/ANNONC/MDH430
P577
2004-11-01T00:00:00Z